Abstract
Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. Methods We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8 months for TPB and 4.0 months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P = 0.001). Median overall survival (OS) was 9.7 months for TPB and 9.4 months for non-TPB regimens (HR 0.53, 95% CI 0.23–1.22, P = 0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for > 6 months (P = 0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for > 12 months (P = 0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. Conclusions These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 46-50 |
| Number of pages | 5 |
| Journal | Gynecologic oncology |
| Volume | 144 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2017 |
Fingerprint
Keywords
- Cervical cancer
- Neuroendocrine
- Small cell carcinoma
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology
Cite this
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. / Frumovitz, Michael; Munsell, M. F.; Burzawa, Jennifer Kelly; Byers, Lauren Averett; Ramalingam, Preetha; Brown, J.; Coleman, Robert.
In: Gynecologic oncology, Vol. 144, No. 1, 01.01.2017, p. 46-50.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix
AU - Frumovitz, Michael
AU - Munsell, M. F.
AU - Burzawa, Jennifer Kelly
AU - Byers, Lauren Averett
AU - Ramalingam, Preetha
AU - Brown, J.
AU - Coleman, Robert
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. Methods We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8 months for TPB and 4.0 months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P = 0.001). Median overall survival (OS) was 9.7 months for TPB and 9.4 months for non-TPB regimens (HR 0.53, 95% CI 0.23–1.22, P = 0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for > 6 months (P = 0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for > 12 months (P = 0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. Conclusions These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.
AB - Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. Methods We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8 months for TPB and 4.0 months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P = 0.001). Median overall survival (OS) was 9.7 months for TPB and 9.4 months for non-TPB regimens (HR 0.53, 95% CI 0.23–1.22, P = 0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for > 6 months (P = 0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for > 12 months (P = 0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. Conclusions These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.
KW - Cervical cancer
KW - Neuroendocrine
KW - Small cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85006106381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006106381&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2016.10.040
DO - 10.1016/j.ygyno.2016.10.040
M3 - Article
C2 - 27823771
AN - SCOPUS:85006106381
VL - 144
SP - 46
EP - 50
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -